Boston Trust Walden Corp Boosts Stake in Bio-Rad Laboratories, Inc. $BIO

Boston Trust Walden Corp raised its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,495 shares of the medical research company’s stock after acquiring an additional 3,657 shares during the period. Boston Trust Walden Corp owned approximately 0.35% of Bio-Rad Laboratories worth $26,062,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. Danske Bank A S purchased a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at about $30,000. Geneos Wealth Management Inc. raised its holdings in shares of Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth approximately $47,000. Farther Finance Advisors LLC boosted its stake in shares of Bio-Rad Laboratories by 76.9% during the fourth quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 80 shares in the last quarter. Finally, Itau Unibanco Holding S.A. increased its holdings in Bio-Rad Laboratories by 57.6% during the fourth quarter. Itau Unibanco Holding S.A. now owns 197 shares of the medical research company’s stock valued at $60,000 after buying an additional 72 shares during the period. Institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

BIO has been the subject of several recent research reports. Royal Bank Of Canada initiated coverage on Bio-Rad Laboratories in a research report on Friday, May 15th. They issued an “outperform” rating and a $320.00 price target for the company. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $375.00 to $300.00 in a report on Tuesday, April 7th. Wells Fargo & Company lowered their price target on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a report on Friday, May 1st. Finally, Weiss Ratings lowered shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $303.33.

Bio-Rad Laboratories Stock Down 0.0%

Shares of BIO stock opened at $296.78 on Friday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $236.73 and a fifty-two week high of $343.12. The firm has a market capitalization of $7.94 billion, a PE ratio of 48.89 and a beta of 1.08. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21. The stock’s 50-day simple moving average is $284.09 and its 200-day simple moving average is $288.04.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). The business had revenue of $592.10 million for the quarter, compared to analysts’ expectations of $589.91 million. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The business’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.54 earnings per share. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 9.42 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.